이다은 (인하대학교)

한빛사논문

조회261

인하대학교

Mol. Ther., Sep 27 2024, S1525-0016(24)00650-6 | https://doi.org/10.1016/j.ymthe.2024.09.026 PD-L1: From Cancer Immunotherapy to Therapeutic Implications in Multiple Disorders

Daeun Lee ^1,#, Minjeong Cho ^3,#, Eunseo Kim ^1,#, Youngbin Seo ¹, Jong-Ho Cha^1,2

¹Department of Biomedical Science, College of Medicine, Program in Biomedical Sciences & Engineering Graduate school,

²Biohybrid Systems Research Center, Inha University, Incheon, 22212, Republic of Korea

³Department of Biological Sciences, Inha University, Incheon 22212, Republic of Korea

^#Daeun Lee, Minjeong Cho, and Eunseo Kim contributed equally to this work.

Corresponding author : Jong-Ho Cha

Abstract

The PD-L1/PD-1 signaling pathway is the gold standard for cancer immunotherapy. Therapeutic antibodies targeting PD-1, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and PD-L1, including atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio) have received FDA approval and are currently being used to treat various cancers. Traditionally, PD-L1 is known as an immune checkpoint protein that binds to the PD-1 receptor on its surface to inhibit the activity of T cells, which are the primary effector cells in antitumor immunity. However, it also plays a role in cancer progression, which goes beyond traditional understanding. Here, we highlight the multifaceted mechanisms of action of PD-L1 in cancer cell proliferation, transcriptional regulation, and systemic immune suppression. Moreover, we consider the potential role of PD-L1 in the development and pathogenesis of diseases other than cancer, explore PD-L1-focused therapeutic approaches for these diseases, and assess their clinical relevance. Through this review, we hope to provide deeper insights into the PD-L1/PD-1 signaling pathway and present a broad perspective on potential therapeutic approaches for cancer and other diseases.

논문정보

형식Review Paper
게재일2024년 09월 (BRIC 등록일 2024-09-30)
연구진국내 연구진
분야 의약학 > 종양의학

댓글 작성 로그인

CV 열람하기

연락처 보기